Abstract 90P
Background
Fruquintinib, a tyrosine kinase inhibitor that specifically inhibits vascular endothelial growth factor receptors, is approved in China for metastatic colorectal cancer (mCRC) patients who failed on standard Chemotherapies. Some retrospective studies have verified its clinical efficacy and safety. However, it remains unclear that how to identify the specific patients who are able to achieve significant survival benefits from it. This real-world study aimed to evaluate the predictive and prognostic factors of fruquintinib in advanced colorectal cancer patients.
Methods
This is a multi-center retrospective study, clinical information and treatment outcome of mCRC patients who received fruquintinib therapy were collected. Multivariate analysis was performed to detect predictive and prognostic factors of fruquintinib in mCRC patients, in which L3 skeletal muscle index (SMI) fluctuations were analyzed as well.
Results
From Jan. 2020 to Jan. 2022, a total of 140 patients were selected and included in this study, of which 76 patients have complete L3 SMI information. Cut-off date was July 30, 2022. Median follow-up time 18.3 months (6 m-29.3 m). Median age was 63 years (32-81 years). The median PFS for the 140 patients was 6.3 m, and the median OS was 12.6 m. The median PFS for the 76 patients with SMI analysis was 6.3 m, and the median OS was 12.9 m. Multivariate analysis suggested that liver metastasis, lymph node metastasis, brain metastasis, decreased SMI > 5%, and baseline CEA level as independent predictors of OS.
Conclusions
This study provides current real-world evidence on the use of fruquintinib in mCRC patients. Liver metastasis, lymph node metastasis, brain metastasis, SMI decreased > 5% and baseline CEA level (> 5 ng/L) were associated with poor prognosis.
Legal entity responsible for the study
The authors.
Funding
This study was supported by the Project of NINGBO Leading Medical&Health Discipline (Project Number: 2022-B09), Medical Scientific Research Foundation of Zhejiang Province (Grant No. 2022KY1135), Wu Jieping Medical Fundation (Project Number: 320.6750.2022-09-06) and Undergraduate Teaching Reform Innovation of Hangzhou Medical College (Project Number: FYJG202219).
Disclosure
All authors have declared no conflicts of interest.